SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE
申请人:AMGEN INC.
公开号:EP1664027A1
公开(公告)日:2006-06-07
ENZYME INHIBITORS
申请人:Kalvista Pharmaceuticals Limited
公开号:EP4017850A1
公开(公告)日:2022-06-29
US7320992B2
申请人:——
公开号:US7320992B2
公开(公告)日:2008-01-22
[EN] SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE<br/>[FR] DERIVES 2,3-DIHYDRO-1H-ISOINDOL-1-ONE SUBSTITUES ET TECHNIQUES D'UTILISATION
申请人:AMGEN INC
公开号:WO2005021532A1
公开(公告)日:2005-03-10
Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.